Allergan LiRIS Hunner's Lesions

What we are studying

A study to test safety and effectiveness of using lidocaine vs. placebo for patients with IC who have hunner's lesions.

Who is Eligible

  • Genders:
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Diagnosed with interstitial cystitis/bladder pain syndrome
  • Must have Hunner's lesions in the bladder due to IC/BPS
  • If no history of Hunner's lesions subject will not qualify

What is involved

  • 15 clinic visits
  • 10 telephone contacts over a period of about 25 weeks
  • Investigational drug or placebo will be inserted and removed up to 3 times over the course of the study
  • Questionnaires
  • Cystoscopies to insert and remove investigational drug or placebo
  • Physical exams with pelvic
  • Questionnaires
  • Laboratory samples
  • And post void residual ultrasound scans.


You will be compensated per visit completed. Depending on how many treatments received, total compensation varies.

Contact Information

Study Coordinator
Janet Shuping
Principal Investigator
Robert J. Evans, M.D.

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.